The estimated Net Worth of Andrew J Greenfield is at least $26.7 Million dollars as of 28 January 2021. Mr. Greenfield owns over 5,000 units of Abiomed stock worth over $14,071,069 and over the last 18 years he sold ABMD stock worth over $9,852,451. In addition, he makes $2,819,600 as Vice President and Chief Commercial Officer at Abiomed.
Andrew has made over 37 trades of the Abiomed stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of ABMD stock worth $331,250 on 28 January 2021.
The largest trade he's ever made was exercising 40,000 units of Abiomed stock on 8 November 2013 worth over $234,400. On average, Andrew trades about 4,444 units every 38 days since 2006. As of 28 January 2021 he still owns at least 36,930 units of Abiomed stock.
You can see the complete history of Mr. Greenfield stock trades at the bottom of the page.
Andrew J. Greenfield serves as Vice President, Chief Commercial Officer of the Company. Mr. Greenfield was appointed as our Vice President and Chief Commercial Officer in April of 2019. He joined us in 2005 and prior to this recent appointment, served as Vice President and General Manager, Global Marketing. In addition to overseeing our global commercial operations, Andrew oversees government affairs, reimbursement, global marketing, Asia Pacific and physician programs. Before joining us, Mr. Greenfield held positions in sales, marketing and finance at GE Healthcare including consulting with large U.S. health systems, eCommerce and Six Sigma from 1999 to 2005. Prior to GE Healthcare, he held positions in sales, marketing and finance at The Boeing Company, including European Country Manager, and is a graduate of the Fiscal Development Program. He received his Bachelor Degree in Finance from the University of Illinois and his Master of Business Administration degree from St. Louis University. Mr. Greenfield also holds a Master Blackbelt in Six Sigma and Change Acceleration Process certification from GE.
As the Vice President and Chief Commercial Officer of Abiomed, the total compensation of Andrew Greenfield at Abiomed is $2,819,600. There are 2 executives at Abiomed getting paid more, with Michael Minogue having the highest compensation of $16,612,800.
Andrew Greenfield is 47, he's been the Vice President and Chief Commercial Officer of Abiomed since 2019. There are 17 older and no younger executives at Abiomed. The oldest executive at Abiomed Inc. is Jeannine Rivet, 72, who is the Independent Director.
Andrew's mailing address filed with the SEC is C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS, MA, 01923.
Over the last 21 years, insiders at Abiomed have traded over $148,507,587 worth of Abiomed stock and bought 232,354 units worth $4,276,073 . The most active insiders traders include Michael R Minogue, Eric A Md Rose, and David M Weber. On average, Abiomed executives and independent directors trade stock every 16 days with the average trade being worth of $5,341,900. The most recent stock trade was executed by Martin P Sutter on 17 February 2022, trading 4,000 units of ABMD stock currently worth $1,258,840.
Abiomed Europe GmbH, Aachen / Germany, as affiliate of Abiomed Inc. headquartered in Danvers, Massachusetts, USA, is a leading medical technology company in the field of circulatory support. Its products aim to enable heart recovery by improving blood circulation and/or heart pump function.
Abiomed executives and other stock owners filed with the SEC include: